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ABSTRACT
Background Upadacitinib is a Janus kinase inhibitor 
under evaluation for the treatment of psoriatic arthritis 
(PsA). We evaluated upadacitinib in patients with PsA 
and prior inadequate response or intolerance to at least 
one biologic disease- modifying antirheumatic drug 
(DMARD).
Methods In this 24- week randomised, placebo- 
controlled, double- blind, phase 3 trial, 642 patients were 
randomised (2:2:1:1) to once per day upadacitinib 15 
mg or 30 mg, placebo followed by upadacitinib 15 mg 
or placebo followed by upadacitinib 30 mg at week 24. 
The primary endpoint was the proportion of patients 
achieving American College of Rheumatology (ACR) 20 
response at week 12. Achievement of minimal disease 
activity (MDA) was assessed at week 24. Treatment- 
emergent adverse events are reported for all patients 
who received at least one dose of trial drug.
Results At week 12, significantly more patients 
receiving upadacitinib 15 mg and 30 mg versus placebo 
achieved ACR20 (56.9% and 63.8% vs 24.1%; p<0.001 
for both comparisons). At week 24, MDA was achieved 
by more upadacitinib 15 mg- treated (25.1%) and 30 
mg- treated patients (28.9%) versus placebo (2.8%; 
p<0.001 for both comparisons). Generally, the rates 
of treatment- emergent adverse events were similar 
with placebo and upadacitinib 15 mg and higher 
with upadacitinib 30 mg at week 24. Rates of serious 
infections were 0.5%, 0.5% and 2.8% with placebo, 
upadacitinib 15 mg and upadacitinib 30 mg, respectively.
Conclusion In this trial of patients with active PsA who 
had inadequate response or intolerance to at least one 
biologic DMARD, upadacitinib 15 mg and 30 mg was 
more effective than placebo over 24 weeks in improving 
signs and symptoms of PsA.
Clinical trial registration number NCT03104374
INTRODUCTION
Psoriatic arthritis (PsA) is a systemic inflammatory 
disease with heterogeneous clinical manifesta-
tions such as plaque psoriasis, arthritis, dactylitis 
and enthesitis. Current treatment guidelines for 
PsA vary, recommending conventional synthetic 
disease- modifying antirheumatic drugs (DMARDs) 
such as methotrexate as initial therapy, followed by 
biologic DMARDs (tumour necrosis factor inhibi-
tors (TNFi), interleukin-12/23 or interleukin-17 
inhibitors) or targeted synthetic DMARDs, such as 
apremilast or tofacitinib, or TNFi initially, followed 
by other approved therapies.1–3 While multiple 
therapeutic choices are now available, additional 
options are needed as under one- third achieving 
minimal disease activity (MDA) in most placebo- 
controlled trials.4–9
Upadacitinib is an oral, reversible Janus kinase 
inhibitor (JAKi) with selectivity for JAK1 over 
JAK2, JAK3 and tyrosine kinase 2,10 approved for 
the treatment of rheumatoid arthritis based on five 
phase 3 studies.11–15 Improvements in multiple 
composite measures, including stringent measures 
Key messages
What is already known about this subject?
 ► Despite the availability of biologic disease- 
modifying antirheumatic drugs (DMARDs) in 
psoriatic arthritis, only a small proportion of 
patients achieve the recommended target of 
minimal disease activity; therefore, additional 
treatment options are needed.
What does this study add?
 ► In this phase 3 trial of patients with psoriatic 
arthritis refractory or intolerant to biologic 
DMARDs, greater efficacy was demonstrated 
for once per day upadacitinib 15 mg and 30 
mg versus placebo for clinical manifestations 
of psoriatic arthritis including musculoskeletal 
symptoms (peripheral arthritis, enthesitis, 
dactylitis and spondylitis), psoriasis, physical 
function, pain, fatigue and quality of life.
How might this impact on clinical practice or 
future developments?
 ► Once per day upadacitinib 15 mg and 30 mg 
demonstrated significant efficacy in patients 
with psoriatic arthritis refractory or intolerant to 
prior biologic DMARD therapy in the 24- week 
placebo- controlled period of this study.
 ► Efficacy was observed as early as week 2. 
Efficacy was demonstrated in all measures of 
the various core clinical domains of psoriatic 
arthritis. More upadacitinib- treated patients 
achieved a state of minimal disease activity.
 ► The safety findings are consistent with the 
known safety profile of upadacitinib observed 
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of low disease activity and remission, as well as patient- reported 
outcomes such as morning stiffness and pain, after treatment 
with upadacitinib 15 mg once per day, in patients with rheuma-
toid arthritis who failed biologic DMARDs were similar to those 
in patients who had failed conventional synthetic DMARDs or 
methotrexate.11–15 We report the results of the SELECT- PsA 2 
trial, a randomised phase 3 trial of upadacitinib in patients with 
active PsA who have had an inadequate response or intolerance 
to at least one biologic DMARD.
PATIENTS AND METHODS
Patients
Eligible patients were 18 years of age or older with active PsA, had 
a diagnosis of PsA with symptom onset for ≥6 months, fulfilled 
the Classification Criteria for Psoriatic Arthritis (CASPAR),16 
had historical or current plaque psoriasis, ≥3 swollen joints (of 
66) and ≥3 tender joints (of 68) at screening and at baseline, and 
an inadequate response or intolerance to at least one biologic 
DMARD. Patients were excluded if they had previous exposure 
to a JAKi, had a history of fibromyalgia, had arthritis with onset 
prior to age 17 years or had diagnosis of inflammatory joint 
disease other than PsA. Online supplemental section 2 provides 
a complete list of eligibility criteria.
Trial design
A multicentre, randomised, double- blind, phase 3 placebo- 
controlled trial at 123 sites in 17 countries has been ongoing 
since April 2017, conducted per the International Conference on 
Harmonization guidelines, applicable regulations and guidelines 
governing clinical trial conduct, and the Declaration of Helsinki. 
All patients provided written informed consent.
Randomisation and treatments
An Interactive Response Technology system was used to assign 
patients, in a 2:2:1:1 ratio, to one of the following regimens: 
upadacitinib 15 mg once per day, upadacitinib 30 mg once per 
day or placebo switched to either upadacitinib 15 mg or 30 mg 
once per day at week 24. Stable background treatment of non- 
steroidal anti- inflammatory drugs, corticosteroids (equivalent to 
≤10 mg/day prednisone) and ≤2 non- biologic DMARDs were 
permitted; background therapy was not required. Concomitant 
biologic therapies were prohibited. Concomitant treatments 
specifically for psoriasis (eg, topicals, light therapy, retinoids) 
were not permitted until after week 16.
Starting at week 16, patients who did not achieve ≥20% 
improvement in tender and swollen joint counts compared with 
baseline at weeks 12 and 16 had background medication(s) 
adjusted or initiated. Starting at week 36, patients who did not 
achieve ≥20% improvement in tender and swollen joint counts 
compared with baseline at two consecutive visits were discon-
tinued from the study. All patients who completed week 56 were 
eligible to remain in the extension period of the trial for up to 3 
years of trial participation in total (online supplemental figure 1).
Randomisation was stratified by extent of psoriasis (≥3%/<3% 
body surface area (BSA)), current use of at least 1 DMARD and 
number of prior biologic DMARDs failed (1 versus >1). The 
trial is ongoing; data presented include the 24- week placebo- 
controlled period during which investigators and the sponsor 
were blinded to treatment assignment.
Assessments
The primary endpoint was the proportion of patients achieving 
American College of Rheumatology (ACR) 20 response at week 
12. Multiplicity- controlled secondary endpoints for each dose 
of upadacitinib versus placebo included: at week 12, change 
from baseline in Health Assessment Questionnaire- Disability 
Index (HAQ- DI)17; Functional Assessment of Chronic Illness 
Therapy- Fatigue (FACIT- F) score18 and Short Form Health 
Survey questionnaire (SF-36) Physical Component Summary 
(PCS) score19; at week 16, proportion of patients achieving a 
Static Investigator Global Assessment (sIGA) of Psoriasis of 0 or 
1 and at least a 2 point improvement from baseline (sIGA 0/1) 
for patients with baseline sIGA ≥220; Psoriasis Area Severity 
Index (PASI)75 response for patients with ≥3% BSA- psoriasis 
at baseline21; and change from baseline in Self- Assessment 
of Psoriasis Symptoms (SAPS) Questionnaire22; and at week 
24, proportion of patients achieving MDA.23 Additional key 
secondary efficacy endpoints included ACR50/70 response 
at week 12 and ACR20 response at week 2. Exploratory 
endpoints were proportion of patients achieving PASI90/100 
response, resolution of enthesitis (defined by Leeds Enthesitis 
Index (LEI)=0) for patients with baseline LEI >024 and Spon-
dyloarthritis Research Consortium of Canada Enthesitis Index 
((SPARCC)=0) for patients with baseline SPARCC Enthesitis 
Index>025 and resolution of dactylitis (defined by Leeds 
Dactylitis Index (LDI)=0) for patients with baseline LDI>0,26 
and change from baseline in individual components of ACR 
response, Disease Activity in Psoriatic Arthritis (DAPSA) 
score,27 and morning stiffness (mean of Bath Ankylosing Spon-
dylitis Disease Activity Index (BASDAI) questions 5 and 6). All 
outcomes are defined in online supplemental table S1.
Adverse events (AEs) and clinical laboratory testing are 
reported through week 24. An independent, external Cardio-
vascular Adjudication Committee blindly adjudicated deaths 
and cardiovascular events per predefined event definitions. 
An internal Gastrointestinal (GI) Perforation Adjudication 
Committee blindly adjudicated reported GI perforation 
events as stated in the GI perforation charter.
Statistical analysis
Efficacy analyses were conducted on all randomised patients 
who had received at least one dose of trial drug. A sample size 
of 630 patients was planned to provide at least 90% power for 
a 20% difference in ACR20 response rate (assuming a placebo 
ACR20 response rate of 20%) and for most of the key secondary 
endpoints (online supplemental section 3).
The overall type I error rate of primary and ranked key 
secondary endpoints was strongly controlled using a graphical 
multiple testing procedure starting with the primary endpoint 
using α/2 for each dose followed by a prespecified α transfer 
path, which included downstream transfer along the endpoint 
sequence within each dose as well as cross- dose transfer (online 
supplemental figure S2). Once an endpoint was claimed signif-
icant, its significance level was transferred to subsequent 
endpoint(s) following the prespecified order and weight. All 
other outcomes were prespecified in the protocol and statistical 
analysis plan without adjustment for multiplicity.
The Cochran- Mantel- Haenszel test adjusting for the stratifica-
tion factor of current DMARD use (yes/no) was used to compare 
treatment binary endpoints. Non- responder imputation was 
used for missing data handling, where patients with missing data 
at the specified week or those who prematurely discontinued 
the trial drug were considered non- responders. For continuous 
endpoints, analyses were conducted using the mixed- effects 
model repeated measures analysis based on observed longitu-
dinal data, which included the fixed effects of treatment, visit, 
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treatment- by- visit interaction, the stratification factor of current 
DMARD use (yes/no) and the continuous fixed covariate of 
baseline measurement. An unstructured variance covariance 
matrix was used. Patients who met the discontinuation criteria 
were considered non- responders.
RESULTS
Patients
Of the 642 patients randomised, 641 received at least one dose of 
trial drug (placebo, n=212; upadacitinib 15 mg, n=211; upad-
acitinib 30 mg, n=218; online supplemental figure S3). Overall, 
Table 1 Demographics and characteristics at baseline
Placebo
N=212
Upadacitinib 15 mg QD
N=211
Upadacitinib 30 mg QD
N=218
Female, n (%) 120 (56.6) 113 (53.6) 115 (52.8)
Age (years) 54.1±11.5 53.0±12.0 53.0±11.9
Race, n (%)
  White 186 (87.7) 183 (86.7) 196 (89.9)
  Black or African American 7 (3.3) 5 (2.4) 5 (2.3)
  American Indian/Alaska Native 0 3 (1.4) 0
  Native Hawaiian or other Pacific Islander 1 (0.5) 1 (0.5) 1 (0.5)
  Asian 17 (8.0) 19 (9.0) 16 (7.3)
  Multiple 1 (0.5) 0 0
Duration of PsA symptoms (years) 14.6±11.7 12.2±8.8 13.3±10.8
Duration since PsA diagnosis (years) 11.0±10.3 9.6±8.4 9.7±8.7
Number of prior failed biologic DMARDs, n (%)
  0* 18 (8.5) 16 (7.6) 17 (7.8)
  1 135 (63.7) 126 (59.7) 130 (59.6)
  2 35 (16.5) 35 (16.6) 46 (21.1)
  ≥3 24 (11.3) 34 (16.1) 25 (11.5)
Monotherapy, n (%) 112 (52.8) 113 (53.6) 120 (55.0)
Any non- biologic DMARD at baseline, n (%)
  MTX alone 75 (35.4) 74 (35.1) 73 (33.5)
  MTX+another non- biologic DMARD 7 (3.3) 6 (2.8) 5 (2.3)
  Non- biologic DMARD other than MTX 18 (8.5) 18 (8.5) 20 (9.2)
MTX dose for patients with concomitant MTX alone at baseline (mg/week)
  Mean 16.26 15.06 16.76
  Median 17.5 15.0 17.5
Steroid use at baseline, n (%) 24 (11.3) 22 (10.4) 13 (6.0)
NSAID use at baseline, n (%) 125 (59.0) 124 (58.8) 129 (59.2)
RF status positive, n (%) 6 (2.8) 11 (5.2) 8 (3.7)
Anti- CCP status positive, n (%) 10 (4.7) 7 (3.3) 5 (2.3)
TJC68 25.3±17.6 24.9±17.3 24.2±15.9
SJC66 12.0±8.9 11.3±8.2 12.9±9.4
hs- CRP >ULN† (mg/L), n (%) 121 (57.1) 126 (59.7) 128 (58.7)
hs- CRP (mg/L) 10.4±18.5 11.2±18.5 10.5±17.2
HAQ- DI 1.23±0.7 1.10±0.6 1.19±0.7
Patient’s assessment of pain (NRS 0–10) 6.6±2.1 6.4±2.1 6.2±2.2
BSA- psoriasis ≥3%, n (%) 131 (61.8) 130 (61.6) 131 (60.1)
  PASI (for baseline BSA- Ps ≥3%) 11.7±11.4 10.1±9.2 8.9±9.1
BSA- psoriasis >0%, n (%) 198 (93.4) 202 (95.7) 202 (92.7)
BSA- psoriasis (for baseline >0%) 12.8±18.4 10.0±15.7 10.0±15.8
sIGA of psoriasis score, n (%)
  0 17 (8.0) 9 (4.3) 16 (7.3)
  1 32 (15.1) 31 (14.7) 38 (17.4)
  2 59 (27.8) 82 (38.9) 78 (35.8)
  3 88 (41.5) 78 (37.0) 77 (35.3)
  4 16 (7.5) 11 (5.2) 9 (4.1)
Presence of enthesitis
  LEI >0, n (%) 144 (67.9) 133 (63.0) 152 (69.7)
  SPARCC Enthesitis Index >0, n (%) 173 (81.6) 172 (81.5) 179 (82.1)
Presence of dactylitis (defined as LDI >0), n (%) 64 (30.2) 55 (26.1) 50 (22.9)
Morning stiffness score‡ 5.8±2.5 6.0±2.5 5.7±2.7
Values are mean±SD unless noted.
*Patients with intolerance but not inadequate response to a biologic DMARD.
†ULN=2.87 mg/L.
‡Morning stiffness score is the mean of BASDAI questions 5 and 6.
Anti- CCP, anti- cyclic citrullinated peptide; ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BSA, body surface area; DMARD, disease- modifying antirheumatic drug; HAQ- DI, Health 
Assessment Questionnaire- Disability Index; hs- CRP, high- sensitivity C- reactive protein; LDI, Leeds Dactylitis Index; LEI, Leeds Enthesitis Index; MTX, methotrexate; NRS, Numeric Rating Scale; NSAID, non- steroidal anti- inflammatory drug; PASI, 
Psoriasis Area Severity Index; Ps, psoriasis; PsA, psoriatic arthritis; QD, once per day; RF, rheumatoid factor; sIGA, Static Investigator Global Assessment; SJC, swollen joint count; SPARCC, Spondyloarthritis Research Consortium of Canada; TJC, 
tender joint count; ULN, upper limit normal.
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543 (84.6%) patients completed week 24 on trial drug. Baseline 
demographics, disease characteristics and disease severity were 
generally balanced across treatment arms (table 1).
Efficacy
At week 12, significantly more patients achieved an ACR20 
response in the upadacitinib 15 mg and 30 mg arms versus the 
placebo arm (56.9%, 63.8% and 24.1%, respectively; p<0.001 
for both upadacitinib arms vs placebo; figure 1, tables 2 and 3). 
By week 2, ACR20 response was achieved by more upadacitinib 
15 mg- treated and 30 mg- treated patients (nominal p<0.001). 
The proportion of patients with ACR20 response continued to 
increase over time in both treatment groups with the plateau of 
response observed at week 12 for the upadacitinib 30 mg group, 
whereas the proportion of patients with ACR20 response in the 
upadacitinib 15 mg group increased through week 20, approx-
imating the response rate in the 30 mg dose group by the end 
of the placebo- controlled period. Subgroup analyses for ACR20 
based on demographic and baseline disease characteristics are 
shown in online supplemental figure S4. Response rates for 
upadacitinib 15 mg and upadacitinib 30 mg were 44.9% and 
64.8% in the subgroup of patients who had failed >1 biologic 
DMARD and 55.8% and 66.7% in the subgroup of patients that 
were on monotherapy; these responses were similar to results in 
the overall population. Additionally, improvements in ACR50 
and ACR70 were observed with both upadacitinib doses versus 
placebo at week 12 (figure 1 and table 3). From week 2 through 
week 24, improvement from baseline in all components of ACR 
response was observed with upadacitinib 15 mg or 30 mg versus 
placebo (online supplemental figure S5).
The 15 mg and 30 mg doses of upadacitinib showed greater 
improvement versus placebo with respect to all key secondary 
endpoints (table 2 and online supplementary material).
By week 12 and through week 24, improvement in psoriasis 
was observed with both upadacitinib doses versus placebo as 
measured by PASI75/90/100 (at week 16, p<0.001 for PASI75 
and nominal p<0.001 for PASI90/100; nominal p<0.001 for all 
the other time points; figure 2) and sIGA 0/1 (p<0.001 at week 
16; nominal p<0.001 for weeks 12 and 24; online supplemental 
figure S6). The changes from baseline in SAPS were greater for 
both upadacitinib arms versus placebo at weeks 16 (p<0.001) 
and 24 (nominal p<0.001; online supplemental figure S7).
Improvements in physical function were observed in patients 
on both doses of upadacitinib versus placebo based on the mean 
change from baseline in HAQ- DI from week 2 through week 24 
(p<0.001 at week 12) and SF-36 PCS at weeks 12 (p<0.001) 
and 24 (nominal p<0.001; online supplemental figure S8). 
Patients on both doses of upadacitinib reported improvements 
in fatigue as assessed by FACIT- F versus placebo at weeks 12 
(p<0.001) and 24 (nominal p<0.001; online supplemental 
figure S9). Mean improvements from baseline in morning stiff-
ness were observed at weeks 12 and 24 (nominal p<0.001; 
online supplemental figure S10).
Resolution of enthesitis using both the LEI and the SPARCC 
enthesitis index and of dactylitis was reported in a higher propor-
tion of patients on either dose of upadacitinib versus placebo 
from week 12 to week 24 (nominal p<0.001; table 3 and online 
supplemental figure S11).
A higher proportion of patients receiving either dose of 
upadacitinib achieved MDA through week 24 versus placebo 
(p<0.001 at week 24; nominal p<0.001 for weeks 12 and 16; 
figure 3).
Mean changes from baseline in the DAPSA score were greater 
with both upadacitinib doses versus placebo through week 24 
(nominal p<0.001 for all time points; figure 4).
Safety
Through week 24, the rate of overall treatment- emergent AEs 
(TEAEs) was higher in the upadacitinib 30 mg arm and rates of 
serious AEs (SAEs) and TEAEs leading to discontinuation of trial 
drug were higher with both upadacitinib doses versus placebo 
(table 4).
The most commonly reported TEAEs were upper respira-
tory tract infection and nasopharyngitis in upadacitinib- treated 
patients (online supplemental table S3). SAEs were reported in 4 
(1.9%) patients on placebo, 12 (5.7%) on upadacitinib 15 mg and 
18 (8.3%) on upadacitinib 30 mg. Serious infections occurred 
in one patient each (0.5%) on placebo and upadacitinib 15 mg 
and six (2.8%) patients on upadacitinib 30 mg. Pneumonia was 




























































































































































Placebo Upadacitinib 15mg QD Upadacitinib 30mg QD
Figure 1 Proportions of patients achieving (A) ACR20 (B) ACR50 and (C) ACR70 response over 24 weeks (NRI). *p≤0.05 for comparison of 
upadacitinib 15 mg once per day versus placebo; #p≤0.05 for comparison of upadacitinib 30 mg once per day versus placebo; †Significant in the 
multiplicity- controlled analysis. ACR20/50/70, 20%/50%/70% improvement in American College of Rheumatology criteria. Results are based on non- 
responder imputation. 95% CIs for response rate were calculated based on normal approximation to the binominal distribution. 95% CIs for response 
rate difference were calculated based on normal approximation. Nominal p value was constructed using Cochran- Mantel- Haenszel test adjusted for 
the main stratification factor of current disease- modifying antirheumatic drug use (yes/no).
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upadacitinib 15 mg and three patients on upadacitinib 30 mg). 
Up to week 24, treatment- emergent opportunistic infections, 
excluding tuberculosis and herpes zoster, included one event 
each of candidiasis of the trachea and oropharyngeal candidiasis, 
both with upadacitinib 30 mg. Herpes zoster was reported in 
two, three and eight patients in the placebo, upadacitinib 15 mg 
and 30 mg arms, respectively; none of the cases were serious. 
One patient on upadacitinib 15 mg and two patients on upad-
acitinib 30 mg had cutaneous disseminated herpes zoster. No 
cases of herpes zoster with central nervous system involvement 
were observed. Hepatic disorders were reported in 3 (1.4%) 
patients on placebo, 4 (1.9%) on upadacitinib 15 mg and 18 
(8.3%) on upadacitinib 30 mg; most were asymptomatic liver 
enzyme elevations.
Malignancies were reported in three patients in each upadac-
itinib arm (upadacitinib 15 mg: one basal cell carcinoma, one 
prostate cancer, one rectal cancer; upadacitinib 30 mg: one 
rectal adenocarcinoma, one ovarian and endometrial cancer, and 
one basal cell carcinoma) and none in the placebo arm. The time 
to event onset for these malignant events was <6 months.
There were no adjudicated gastrointestinal perforations 
reported through week 24. One case of major adverse cardiovas-
cular event (MACE; 0.5%, non- fatal myocardial infarction) and 
one case of venous thromboembolic event (VTE; 0.5%; pulmo-
nary embolism) were reported in the upadacitinib 15 mg arm; 
both patients had at least one risk factor (eg, obesity, hyperten-
sion or hypercholesterolaemia) for MACE or VTE, respectively. 






ACR20 response at week 12
  N 212 211 218
  n (%) 51 (24.1) 120 (56.9) 139 (63.8)
  Response rate mean difference vs placebo 
(95% CI)
32.8 (24.0 to 
41.6)
39.7 (31.1 to 
48.3)
  P value <0.001 <0.001
HAQ- DI change from baseline at week 12
  N 180 199 204
  LS mean (95% CI) −0.10 (−0.16 to 
−0.03)
−0.30 (−0.37 to 
−0.24)
−0.41 (−0.47 to 
−0.35)
  LS mean difference (95% CI) −0.21 (−0.30 to 
−0.12)
−0.31 (−0.40 to 
−0.22)
  P value <0.001 <0.001
FACIT- F score change from baseline at 
week 12
  N 184 201 206
  LS mean (95% CI) 1.3 (0.1 to 2.5) 5.0 (3.8 to 6.1) 6.1 (4.9 to 7.2)
  LS mean difference (95% CI) 3.7 (2.0 to 5.4) 4.8 (3.1 to 6.4)
  P value <0.001 <0.001
SF-36 PCS score change from baseline at 
week 12
  N 185 201 206
  LS mean (95% CI) 1.6 (0.6 to 2.7) 5.2 (4.1 to 6.2) 7.1 (6.1 to 8.1)
  LS mean difference (95% CI) 3.5 (2.1 to 5.0) 5.4 (4.0 to 6.9)
  P value <0.001 <0.001
Proportion of patients achieving sIGA of psoriasis score of 0 or 1 and at least a 2- point improvement from 
baseline at week 16 (for patients with baseline sIGA ≥2)
  N 163 171 164
  n (%) 15 (9.2) 63 (36.8) 66 (40.2)
  Response rate mean difference (95% CI) 27.6 (19.2 to 
36.1)
31.0 (22.3 to 
39.8)
  P value <0.001 <0.001
PASI75 response at week 16 (for patients 
with ≥3% BSA- psoriasis at baseline)
  N 131 130 131
  n (%) 21 (16.0) 68 (52.3) 74 (56.5)
  Response rate mean difference (95% CI) 36.3 (25.6 to 
46.9)
40.5 (29.9 to 
51.0)
  P value <0.001 <0.001
Self- Assessment of Psoriasis Symptoms score 
change from baseline at week 16
  N 182 191 200
  LS mean (95% CI) −1.5 (−4.7 to 1.8) −24.4 (−27.5 to 
−21.2)
−29.7 (−32.8 to 
−26.6)
  LS mean difference (95% CI) −22.9 (−27.4 to 
−18.4)
−28.2 (−32.7 to 
−23.8)
  P value <0.001 <0.001
Proportion of patients achieving minimal 
disease activity at week 24
  N 212 211 218
  n (%) 6 (2.8) 53 (25.1) 63 (28.9)
  Response rate mean difference (95% CI) 22.3 (16.0 to 
28.6)
26.1 (19.7 to 
32.5)
  P value <0.001 <0.001
ACR20, 20% improvement in American College of Rheumatolog criteria; BSA, body surface area; FACIT- F, Functional 
Assessment of Chronic Illness Therapy- Fatigue; HAQ- DI, Health Assessment Questionnaire- Disability Index; LS, least 
squares; PASI75, 75% improvement in Psoriasis Area and Severity Index ; QD, once per day; SF36- PCS, 36- Item Short 
Form Health Survey Physical Component Summary score; sIGA, Static Investigator Global Assessment.






ACR50 response rate at 
week 12
  N 212 211 218
  n (%) 10 (4.7) 67 (31.8) 82 (37.6)
  Response rate mean 
difference (95% CI)
27.0 (20.1 to 33.9) 32.9 (25.9 to 39.9)
  Nominal p value <0.001 <0.001
ACR70 response rate at 
week 12
  N 212 211 218
  n (%) 1 (0.5) 18 (8.5) 36 (16.5)
  Response rate mean 
difference (95% CI)
8.1 (4.2 to 11.9) 16.0 (11.0 to 21.1)
  Nominal p value <0.001 <0.001
ACR20 response rate at 
week 2
  N 212 211 218
  n (%) 23 (10.8) 69 (32.7) 73 (33.5)
  Response rate mean 
difference (95% CI)
21.9 (14.3 to 29.4) 22.6 (15.1 to 30.2)
  Nominal p value <0.001 <0.001
Exploratory endpoints
Resolution of enthesitis 
at week 12 (defined as 
LEI=0)
  N 144 133 152
  n (%) 29 (20.1) 52 (39.1) 73 (48.0)
  Response rate 
difference (95% CI)
19.0 (8.4 to 29.5) 27.9 (17.6 to 38.2)
  Nominal p value <0.001 <0.001
Resolution of dactylitis 
at week 12 (defined as 
LDI=0)
  N 64 55 50
  n (%) 23 (35.9) 35 (63.6) 38 (76.0)
  Response rate 
difference (95% CI)
27.7 (10.4 to 45.0) 40.1 (23.4 to 56.7)
  Nominal p- value <0.001 <0.001
ACR20/50/70, 20%/50%/70% improvement in American College of Rheumatology 
criteria; LDI, Leeds Dactylitis Index; LEI, Leeds Enthesitis Index; QD, once per day.
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Over the 24- week period, one death was reported in the placebo 
arm related to a motor vehicle accident.
Generally, mean haemoglobin, neutrophil, lymphocyte and 
platelet levels remained within normal limits from baseline 
through week 24 in all treatment arms (online supplemental 
figure S12 and online supplemental table S5). There were two 
patients with grade 3 decreases in haemoglobin values in the 
upadacitinib 30 mg arm (online supplemental table S4). Grade 3 
decreases in neutrophils were reported in one patient on placebo 
(0.5%), two patients on upadacitinib 15 mg (1.0%) and four 
patients on upadacitinib 30 mg (1.8%). No patients had grade 
4 decreases in platelets, leucocytes, neutrophils or lymphocytes.
Isolated grade 3 increases in alanine aminotransferase or 
aspartate aminotransferase were observed in ≤1% of the patients 
among the treatment arms, and no grade 4 increases were 
observed (online supplemental table S4). No Hy’s law cases were 
reported. Grade 3 increases in creatine phosphokinase (CPK) 
values were reported in one (0.5%), one (0.5%) and five (2.3%) 
patients in the placebo, and upadacitinib 15 mg and 30 mg arms, 






















































































































Placebo Upadacitinib 15mg QD Upadacitinib 30mg QD
A. B. C.
Figure 2 Proportion of patients achieving (A) PASI75, (B) PASI90 and (C) PASI100. response over 24 weeks. *p≤0.05; for upadacitinib 15 mg QD 
versus placebo; #p≤0.05; for upadacitinib 30 mg QD versus placebo; †significant in the multiplicity- controlled analysis. After week 16, assessments 
have been performed. Patients may use concomitant treatments specifically for psoriasis per investigator judgement. Results are based on non- 
responder imputation. 95% CIs for response rate were calculated based on normal approximation to the binominal distribution. 95% CIs for response 
rate difference were calculated based on normal approximation. Nominal p value was constructed using Cochran- Mantel- Haenszel test adjusted for 
the main stratification factor of current disease- modifying antirheumatic drug use (yes/no). PASI75/90/100, 75%/90%/100% improvement in Psoriasis 









































Figure 3 Proportion of patients achieving minimal disease activity 
(MDA) over 24 weeks. *p≤0.05; for upadacitinib 15 mg QD versus 
placebo; #p≤0.05; for upadacitinib 30 mg QD versus placebo; 
†significant in the multiplicity- controlled analysis. Results for MDA at 
week 24 are based on non- responder imputation with additional rescue 
handling, where MDA at week 24 for patients rescued at week 16 is 
imputed as non- responder. 95% CIs for response rate were calculated 
based on normal approximation to the binominal distribution. 95% 
CIs for response rate difference were calculated based on normal 
approximation. Nominal p value was constructed using Cochran- 
Mantel- Haenszel test adjusted for the main stratification factor of 

















































Figure 4 Change from baseline in Disease Activity in Psoriatic Arthritis 
(DAPSA) score. *p≤0.05; for upadacitinib 15 mg QD versus placebo; 
#p≤0.05; for upadacitinib 30 mg QD versus placebo. Within group least 
square mean and 95% CI, and between group least square mean, 95% 
CI and nominal p value are based on mixed- effect model repeated 
measurement (MMRM) analysis with unstructured variance- covariance 
matrix, including treatment, visit, treatment- by- visit interaction, the 
stratification factor current disease- modifying antirheumatic drug use 
(yes/no) as fixed factors and the continuous fixed covariate of baseline 
measurement. QD, once per day.
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two patients with placebo and one patient with upadacitinib 15 
mg. None led to discontinuation of trial drug, and there were no 
events of rhabdomyolysis. Slight mean elevations in low- density 
lipoprotein cholesterol (LDL- C) and high- density lipoprotein 
cholesterol (HDL- C) were observed in the upadacitinib arms 
versus the placebo arm (online supplemental figure S13). The 
ratios of LDL- C:HDL- C and total cholesterol:HDL- C generally 
remained constant through week 24.
DISCUSSION
In this phase 3 trial of patients refractory or intolerant to biologic 
DMARDs, greater efficacy was demonstrated for upadacitinib 15 
mg and 30 mg once per day versus placebo for clinical manifes-
tations of PsA including musculoskeletal symptoms (peripheral 
arthritis, enthesitis, dactylitis and spondylitis), psoriasis, physical 
function, pain, fatigue and quality of life.
Despite the advent of biologic DMARDs in PsA, many patients 
are either refractory or develop refractoriness to such treatment, 
underscoring the need for new therapy options. Both upadac-
itinib doses demonstrated efficacy in this particularly refrac-
tory population, wherein approximately 31% of the patients 
had failed ≥2 biologic DMARDs. Furthermore, treatment with 
both upadacitinib doses resulted in improvements over placebo 
in more rigorous measures of disease control, as demonstrated 
by the ACR70, PASI100, sIGA 0/1, resolution of enthesitis and 
dactylitis, and MDA. Notably, efficacy was achieved with both 
upadacitinib doses as monotherapy and in combination with 
non- biologic DMARDs. Both upadacitinib doses also provided 
rapid efficacy on arthritis signs/symptoms, as evidenced by 
greater improvement of ACR20 compared with placebo at week 
2.
Upadacitinib 30 mg resulted in numerically greater efficacy 
when compared with 15 mg for the primary and key secondary 
endpoints. Upadacitinib showed improvement in psoriasis 
similar to that observed in recent studies of biologics and small 
molecules in patients with PsA and previous inadequate response 
Table 4 Safety summary through week 24
Placebo
N=212
Upadacitinib 15 mg QD
N=211
Upadacitinib 30 mg QD
N=218
Patients with adverse events (AE), n (%)
Any AE 139 (65.6) 135 (64.0) 170 (78.0)
Serious AE 4 (1.9) 12 (5.7) 18 (8.3)
AE leading to discontinuation of trial drug 11 (5.2) 15 (7.1) 20 (9.2)
Deaths 1 (0.5) 0 0
Infection 73 (34.4) 71 (33.6) 108 (49.5)
  Serious infection 1 (0.5) 1 (0.5) 6 (2.8)
  Opportunistic infection excl. tuberculosis and herpes zoster 0 0 2 (0.9)
  Herpes zoster 2 (0.9) 3 (1.4) 8 (3.7)
  Active tuberculosis 0 0 0
Hepatic disorder 3 (1.4) 4 (1.9) 18 (8.3)
Malignancy 0 3 (1.4) 3 (1.4)
  Non- melanoma skin cancer 0 1 (0.5) 1 (0.5)
  Malignancy other than NMSC 0 2 (0.9) 2 (0.9)
  Lymphoma* 0 1 (0.5) 0
Anaemia 2 (0.9) 4 (1.9) 14 (6.4)
Neutropenia 1 (0.5) 2 (0.9) 6 (2.8)
Lymphopenia 0 2 (0.9) 2 (0.9)
Creatine phosphokinase elevation 4 (1.9) 4 (1.9) 12 (5.5)
Renal dysfunction 1 (0.5) 0 1 (0.5)
MACE (adjudicated) 0 1 (0.5) 0
VTE (adjudicated) 0 1 (0.5) 0
Laboratory data (LS mean change from baseline to week 24±SD)
Haemoglobin, g/L −0.7±7.44 −3.6±9.45 −5.5±10.78
Neutrophils, 109/L −0.056±1.6435 −0.286±1.9578 −0.610±2.0242
Lymphocytes, 109/L −0.076±0.5484 −0.028±0.5460 −0.057±0.5403
Platelets, 109/L 1.7±59.35 8.4±51.59 18.3±72.08
LDL- C, mmol/L 0.003±0.6839 0.219±0.6567 0.453±0.9283
HDL- C, mmol/L −0.008±0.2278 0.199±0.2599 0.243±0.3451
ALT, U/L −0.7±10.28 6.8±16.05 9.1±16.45
AST, U/L −0.1±8.41 6.5±22.17 8.3±13.29
Creatinine, umol/L 2.2±10.87 4.7±9.19 5.3±9.48
Creatine phosphokinase, U/L −19.9±140.87 166.8±1198.70 138.7±165.85
AEs were coded per the Medical Dictionary for Regulatory Activities. Laboratory data was graded using the Common Toxicity Criteria of the National Cancer Institute 4.03.
*In the once per day upadacitinib 15 mg arm, one event of treatment- emergent lymphocyte morphology abnormal was identified; per the investigator, no further diagnosis was 
made.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; HDL- C, high- density lipoprotein cholesterol; LDL- C, low- density lipoprotein cholesterol; LS, least squares; MACE, 
major adverse cardiovascular events (defined as non- fatal myocardial infarction, non- fatal stroke and cardiovascular death); NMSC, non- melanoma skin cancer; QD, once per day; 
VTE, venous thromboembolic event (defined as deep vein thrombosis and pulmonary embolism).
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to biologic DMARDs.28–30 However, the efficacy differences in 
musculoskeletal manifestations between the upadacitinib doses 
appear to decrease by week 24. Dose- dependent efficacy will be 
further evaluated with long- term data.
The safety profile of upadacitinib was generally consistent with 
results reported previously in rheumatoid arthritis trials.11–14 
More serious infections, opportunistic infections and herpes 
zoster events were reported with upadacitinib 30 mg compared 
with upadacitinib 15 mg and placebo; however, percentages of 
malignancy and lymphopenia were the same in the upadacitinib 
arms. Although the sample size and trial duration may not be 
enough to make a determination from this study, there was a 
lack of MACE and VTE reports in the upadacitinib 30 mg arm, 
suggesting no dose- dependent increased risk of these cardiovas-
cular events with upadacitinib therapy. Few grade 3 or 4 labora-
tory abnormalities were seen in either upadacitinib arm.
Due to the 24- week duration of the placebo- controlled 
portion of this trial, limited safety conclusions may be made for 
events with longer latency or rare events. Long- term safety and 
efficacy of upadacitinib in patients with PsA are continuing to be 
evaluated in the ongoing extension phase. Further, this trial did 
not assess the effect of upadacitinib on radiographic progression 
compared with that of placebo. However, radiographic progres-
sion was evaluated in a parallel trial (NCT03104400) registered 
on  clinicaltrials. gov.
In summary, in a PsA population refractory or intolerant to 
prior biologic DMARD therapy, upadacitinib 15 mg and 30 
mg once per day, with or without concomitant non- biologic 
DMARD therapy, showed rapid improvements versus placebo 
as measured by ACR20 response and efficacy across all clinical 
domains of PsA, including rigorous levels of efficacy in musculo-
skeletal and psoriatic skin disease measures as well as of compre-
hensive disease control. No new safety signals were identified 
compared with what has been observed with upadacitinib in 
rheumatoid arthritis.
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